Generic vs Brand-Name Drugs
What the science says about bioequivalence, therapeutic substitution, narrow-TI drug switching, and the regulatory framework that governs generic approvals.
What is a Generic Drug?
A generic drug is a medicine that contains the same active ingredient in the same dosage form, strength, and route of administration as an already-approved brand-name drug (the reference listed drug, or RLD). Generics are approved after the originator's patents and market exclusivity periods expire, typically 20 years from the patent filing date — though supplemental patents and paediatric exclusivity can extend effective protection beyond this.
Generics may differ in:
- Excipients (fillers, binders, coatings, dyes)
- Tablet/capsule shape and colour
- Packaging and labelling
- Inactive ingredients (not the API)
- Manufacturer and manufacturing site
- Active pharmaceutical ingredient (API) — same salt/ester form usually required
- Dosage form (oral tablet vs tablet; IV vs IV)
- Route of administration
- Strength
- Labelling (indications, dosing, contraindications must mirror RLD)
The FDA Abbreviated New Drug Application (ANDA) process governs generic approvals in the United States. The EMA has an equivalent procedure in Europe. The FDA Orange Book lists all approved drug products with therapeutic equivalence ratings.
Bioequivalence Standards
The FDA's bioequivalence (BE) standard requires that the 90% confidence interval for the ratio of the generic's pharmacokinetic parameters (AUC0-∞ and Cmax) to the brand's falls within 80–125%. This is a statistical criterion, not a guarantee of exact equivalence:
In practice, the observed geometric mean ratio in approved generics is usually between 95% and 105%, and the mean difference between a generic and its brand is approximately 3.5% for AUC and 4.3% for Cmax, according to an FDA analysis of 2,070 BE studies. This is far smaller than typical patient-to-patient PK variability.
Generic variability is dwarfed by normal inter-patient variability in any practice setting.
AB-rated equivalence
The FDA Orange Book assigns each generic an equivalence code. A rating of AB means the generic is therapeutically equivalent to the brand and may be substituted without prescriber intervention in all US states. A rating of BX or B means data are insufficient to establish equivalence — substitution should be avoided.
Narrow Therapeutic Index (NTI) Drugs
NTI drugs are those where small differences in dose or concentration can lead to serious therapeutic failures or adverse reactions. The FDA requires tighter bioequivalence criteria (90% CI within 90–111.1%) for these drugs, acknowledging the reduced margin for error.
INR changes with small AUC shifts. Monitor INR on any formulation switch. CPIC guideline →
Non-linear (Michaelis-Menten) kinetics: AUC disproportionate to dose changes near saturation. Check free level. Epilepsy Foundation →
Autoinducer of CYP3A4; complex kinetics. Substitution can precipitate breakthrough seizures. ILAE →
FDA requires NTI criteria and mandates inter-brand and intra-brand bioequivalence testing. Small TSH changes clinically significant in thyroid cancer. ATA →
Narrow therapeutic window (0.6–1.2 mEq/L). Toxicity above 1.5 mEq/L. Extended-release formulations have different PK profiles to immediate-release. BAP lithium guidelines →
Highly variable oral bioavailability (5–67%). Extended-release (Envarsus, Astagraf) ≠ immediate-release Prograf in PK profile. FDA-approved 1:1 conversion guidance exists. Transplantation Journal →
Generic Approval Process
- 1 Patent expiry / Paragraph IV certification
Generic applicants file an ANDA and certify that the brand's patents are invalid or will not be infringed. The first generic to file a Paragraph IV certification earns 180 days of market exclusivity. FDA Paragraph IV overview
- 2 Bioequivalence study
Two-period crossover study in ~24–36 healthy volunteers (fasted and fed). AUC and Cmax measured; 90% CI calculated. Some drugs require fed/fasted, multiple strength, or patient population studies. FDA BE study guidance
- 3 Manufacturing site inspection
FDA inspects the manufacturing facility for cGMP compliance. This is a critical quality-assurance step — the same drug can have variable quality across manufacturing sites. FDA cGMP inspection programme
- 4 ANDA approval and Orange Book listing
On approval, the drug is listed in the FDA Orange Book with an AB rating. State pharmacy substitution laws then determine whether pharmacists can automatically substitute without prescriber consent.
Common Myths
This is a misreading of the 80–125% bioequivalence window, which assumes the worst-case at both limits simultaneously. The FDA's own analysis of 2,070 BE studies found the actual mean difference is only 3.5% for AUC — far less than the allowed range, and far less than normal inter-patient variability.
All FDA-approved manufacturers — brand and generic — must comply with current Good Manufacturing Practice (cGMP) regulations. Both are subject to periodic FDA inspections. Brand drugs manufactured overseas are held to the same standard as domestic generics.
Excipients can affect dissolution rate, tablet disintegration, coating stability, and absorption in certain patient populations. Patients with known allergies to dyes (FD&C Yellow #5) or lactose intolerance need formulations free of those excipients. Excipients can be clinically relevant — but are rarely the explanation for perceived therapeutic differences. The FDA inactive ingredient database lists all excipients by product.
Professional societies including the American Epilepsy Society and ILAE recommend that antiepileptic drug formulation changes in stable patients should be made with prescriber awareness and patient monitoring. This is not because generics are inferior, but because any formulation change in NTI drugs warrants clinical vigilance.
FAQ
Are generic drugs as effective as brand-name drugs?
Yes, for the vast majority of drugs. FDA requires that the generic's AUC and Cmax ratios to the brand fall within 80–125% (90% CI). In practice, the mean difference is only about 3.5% — less than normal patient-to-patient variability. Large meta-analyses and the FDA's own review consistently show no clinically meaningful differences in outcomes.
What does bioequivalence mean?
Two formulations are bioequivalent if they deliver the same amount of active drug to the systemic circulation (AUC) at a similar rate (Cmax), within the 80–125% confidence interval standard. It does not mean identical — it means any difference is not expected to be clinically significant for most patients.
Are there drugs where generic substitution should be avoided?
Special caution applies to NTI drugs: warfarin, phenytoin, carbamazepine, levothyroxine, tacrolimus, cyclosporine, lithium, and digoxin. For these, the FDA uses tighter BE criteria and clinical monitoring is recommended when switching formulations — even between two generics. Advise patients to inform their pharmacist if they are on these drugs.
Why are generics much cheaper than brand drugs?
Generics do not bear the R&D and clinical trial costs of the originator. They rely on the existing safety and efficacy data. Price competition between multiple generic manufacturers after patent expiry typically reduces costs by 80–90% compared to the brand.
How do I know if a generic is approved as equivalent?
Check the FDA Orange Book. An AB rating means the generic is therapeutically equivalent to the RLD. A rating of B or BX indicates insufficient data — substitution should be avoided. Most pharmacy dispensing systems link to Orange Book data.